These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31883804)

  • 21. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
    Stone RM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
    Dillon LW; Higgins J; Nasif H; Othus M; Beppu L; Smith TH; Schmidt E; Valentine Iii CC; Salk JJ; Wood BL; Erba HP; Radich JP; Hourigan CS
    Haematologica; 2024 Feb; 109(2):401-410. PubMed ID: 37534515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
    Roug AS; Ommen HB
    Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Sun Y; Zhu G; Zhong H
    Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurable residual disease testing in acute myeloid leukaemia.
    Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
    Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
    Fasan O
    Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Tools for Diagnosis and Monitoring of AML.
    Guijarro F; Garrote M; Villamor N; Colomer D; Esteve J; López-Guerra M
    Curr Oncol; 2023 May; 30(6):5201-5213. PubMed ID: 37366878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.
    Schwind S; Jentzsch M; Bach E; Stasik S; Thiede C; Platzbecker U
    Curr Treat Options Oncol; 2020 Jan; 21(1):8. PubMed ID: 32002673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
    Ganzel C; Sun Z; Baslan T; Zhang Y; Gönen M; Abdel-Wahab OI; Racevskis J; Garrett-Bakelman F; Lowe SW; Fernandez HF; Ketterling R; Luger SM; Litzow M; Lazarus HM; Rowe JM; Tallman MS; Levine RL; Paietta E
    Leuk Res; 2022 Dec; 123():106971. PubMed ID: 36332294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
    Meddi E; Savi A; Moretti F; Mallegni F; Palmieri R; Paterno G; Buzzatti E; Del Principe MI; Buccisano F; Venditti A; Maurillo L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The present and future of measurable residual disease testing in acute myeloid leukemia.
    Blachly JS; Walter RB; Hourigan CS
    Haematologica; 2022 Dec; 107(12):2810-2822. PubMed ID: 36453518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
    Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
    Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
    Kayser S; Walter RB; Stock W; Schlenk RF
    Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.
    Dillon LW; Hayati S; Roloff GW; Tunc I; Pirooznia M; Mitrofanova A; Hourigan CS
    Haematologica; 2019 Feb; 104(2):297-304. PubMed ID: 30171026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.